Key facts
- This page summarizes Bryan Giraudo's Form 4 filing for Protagonist Therapeutics, Inc (PTGX).
- 8 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 11 May 2026, 20:25.
Bryan Giraudo - 07 May 2026 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)
- Reporting relationship
- Director
- Issuer ticker
- PTGX
- Reported as of
- 07 May 2026
- Net transaction value
- -$5,918,880
- SEC form
- 4
- Accepted by SEC
- 11 May 2026, 20:25:57 UTC
- Prior SEC filing
- 20 Mar 2026
- Next SEC filing
- 26 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Gosling, Attorney-in-Fact for Bryan Giraudo
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bryan Giraudo filed Form 4 for Protagonist Therapeutics, Inc (PTGX) on 11 May 2026.
Change
- Previous filing in this sequence was filed on 20 Mar 2026.
- Current net transaction value: -$5,918,880.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001740847
Primary reporting owner
Giraudo Bryan
- Relationship
- Director
- Address
- C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK
- Signature
- /s/ Matthew Gosling, Attorney-in-Fact for Bryan Giraudo
- Signature date
- 11 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PTGX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +24,000
- Change %
- +307%
- Price
- $6.45*
- Shares after
- 31,825
- Date
- 07 May 2026
- Ownership
- Direct
- Footnotes
- F1
PTGX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +12,000
- Change %
- +38%
- Price
- $6.98*
- Shares after
- 43,825
- Date
- 07 May 2026
- Ownership
- Direct
PTGX
transaction
Common Stock
Sale
- Transaction value
- $3,605,040
- Shares
- -36,000
- Change %
- -56%
- Price
- $100.14
- Shares after
- 27,825
- Date
- 07 May 2026
- Ownership
- Direct
- Footnotes
- F2
PTGX
transaction
Common Stock
Sale
- Transaction value
- $1,200,840
- Shares
- -12,000
- Change %
- -67%
- Price
- $100.07
- Shares after
- 6,000
- Date
- 07 May 2026
- Ownership
- By Bryan & Courtney Giraudo Trust
- Footnotes
- F1
PTGX
transaction
Common Stock
Sale
- Transaction value
- $600,000
- Shares
- -6,000
- Change %
- -100%
- Price
- $100.00
- Shares after
- 0
- Date
- 08 May 2026
- Ownership
- By Bryan & Courtney Giraudo Trust
PTGX
transaction
Common Stock
Sale
- Transaction value
- $513,000
- Shares
- -5,130
- Change %
- -29%
- Price
- $100.00
- Shares after
- 12,695
- Date
- 08 May 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PTGX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -24,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 07 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,000
- Exercise price
- $6.45
- Footnotes
- F3
PTGX
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -12,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 07 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,000
- Exercise price
- $6.98
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Reflects 10,000 shares of common stock that were previously held directly by the Reporting Person and which were transferred to the Bryan & Courtney Giraudo Trust.
Footnote F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.69 to $104.67. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Footnote F3
These stock options are fully vested.